Caitlin C Murphy1,2, David E Gerber1,2,3, Sandi L Pruitt1,2. 1. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas. 2. Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas. 3. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
Abstract
Importance: The US cancer survivor population is rapidly growing. Cancer survivors are frequently excluded from cancer clinical trials and observational research. Objective: To examine prevalence of prior cancer among individuals newly diagnosed with cancer. Design, Setting, and Participants: Linked observations across the population-based Surveillance, Epidemiology, and End Results (SEER) program of cancer registries (1975-2013) for 740 990 persons newly diagnosed with cancer from January 2009 through December 2013. Prevalence of prior cancer was estimated by age (<65 years vs ≥65 years) and incident cancer type. Main Outcomes and Measures: Prevalence of prior cancer was derived from SEER sequence numbers, which represent the order of all primary reportable tumors diagnosed in a lifetime. Incident cancers were categorized as: (1) first or only primary; (2) second order or higher primary in the same cancer site; and (3) second order or higher primary in a different cancer site. Results: Of 765 843 incident cancers diagnosed between 2009 and 2013, 141 021 (18.4%) represented a second order or higher primary cancer. Overall, approximately one-fourth (25.2%) of older (≥65 years) and 11% of younger adults newly diagnosed with cancer had a history of prior cancer. Prevalence of prior cancer ranged from 3.5% to 36.9% according to incident cancer type and age, with most prior cancers diagnosed in a different cancer site. Conclusions and Relevance: A substantial proportion of patients diagnosed with incident cancer in the United States have survived a prior cancer. These patients may be excluded from clinical trials and underrepresented in observational research, and little is known about their treatment and survivorship needs. Understanding the nature and impact of prior cancer is critical to improving clinical trial accrual and generalizability, disease outcomes, and patient experience.
Importance: The US cancer survivor population is rapidly growing. Cancer survivors are frequently excluded from cancer clinical trials and observational research. Objective: To examine prevalence of prior cancer among individuals newly diagnosed with cancer. Design, Setting, and Participants: Linked observations across the population-based Surveillance, Epidemiology, and End Results (SEER) program of cancer registries (1975-2013) for 740 990 persons newly diagnosed with cancer from January 2009 through December 2013. Prevalence of prior cancer was estimated by age (<65 years vs ≥65 years) and incident cancer type. Main Outcomes and Measures: Prevalence of prior cancer was derived from SEER sequence numbers, which represent the order of all primary reportable tumors diagnosed in a lifetime. Incident cancers were categorized as: (1) first or only primary; (2) second order or higher primary in the same cancer site; and (3) second order or higher primary in a different cancer site. Results: Of 765 843 incident cancers diagnosed between 2009 and 2013, 141 021 (18.4%) represented a second order or higher primary cancer. Overall, approximately one-fourth (25.2%) of older (≥65 years) and 11% of younger adults newly diagnosed with cancer had a history of prior cancer. Prevalence of prior cancer ranged from 3.5% to 36.9% according to incident cancer type and age, with most prior cancers diagnosed in a different cancer site. Conclusions and Relevance: A substantial proportion of patients diagnosed with incident cancer in the United States have survived a prior cancer. These patients may be excluded from clinical trials and underrepresented in observational research, and little is known about their treatment and survivorship needs. Understanding the nature and impact of prior cancer is critical to improving clinical trial accrual and generalizability, disease outcomes, and patient experience.
Authors: Cathy J Bradley; K Robin Yabroff; Angela B Mariotto; Christopher Zeruto; Quyen Tran; Joan L Warren Journal: J Clin Oncol Date: 2017-01-03 Impact factor: 44.544
Authors: Corinne R Leach; Kathryn E Weaver; Noreen M Aziz; Catherine M Alfano; Keith M Bellizzi; Erin E Kent; Laura P Forsythe; Julia H Rowland Journal: J Cancer Surviv Date: 2014-10-16 Impact factor: 4.442
Authors: Caitlin C Murphy; Linda C Harlan; Jennifer L Lund; Charles F Lynch; Ann M Geiger Journal: J Natl Cancer Inst Date: 2015-07-23 Impact factor: 13.506
Authors: George L Jackson; L Douglas Melton; David H Abbott; Leah L Zullig; Diana L Ordin; Steven C Grambow; Natia S Hamilton; S Yousuf Zafar; Ziad F Gellad; Michael J Kelley; Dawn Provenzale Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Janet S de Moor; Angela B Mariotto; Carla Parry; Catherine M Alfano; Lynne Padgett; Erin E Kent; Laura Forsythe; Steve Scoppa; Mark Hachey; Julia H Rowland Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-27 Impact factor: 4.254
Authors: Sun Hee Rim; K Robin Yabroff; Sabitha Dasari; Xuesong Han; Kristin Litzelman; Donatus U Ekwueme Journal: Prev Med Date: 2019-03-16 Impact factor: 4.018
Authors: Ronald M Kline; Neeraj K Arora; Cathy J Bradley; Eden R Brauer; Darci L Graves; Natasha Buchanan Lunsford; Mary S McCabe; Shelley Fuld Nasso; Larissa Nekhlyudov; Julia H Rowland; Rebekkah M Schear; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2018-12-01 Impact factor: 13.506
Authors: Sandi L Pruitt; Hong Zhu; Daniel F Heitjan; Asal Rahimi; Bhumika Maddineni; Anna Tavakkoli; Ethan A Halm; David E Gerber; Danyi Xiong; Caitlin C Murphy Journal: Breast Cancer Res Treat Date: 2021-02-23 Impact factor: 4.872
Authors: Kara N Maxwell; Brandon M Wenz; Abha Kulkarni; Bradley Wubbenhorst; Kurt D'Andrea; Benita Weathers; Noah Goodman; Joseph Vijai; Jenna Lilyquist; Steven N Hart; Thomas P Slavin; Kasmintan A Schrader; Vignesh Ravichandran; Tinu Thomas; Chunling Hu; Mark E Robson; Paolo Peterlongo; Bernardo Bonanni; James M Ford; Judy E Garber; Susan L Neuhausen; Payal D Shah; Angela R Bradbury; Angela M DeMichele; Kenneth Offit; Jeffrey N Weitzel; Fergus J Couch; Susan M Domchek; Katherine L Nathanson Journal: JCO Precis Oncol Date: 2020-08-19